



September 27, 2019

Pharmacy Announcement

Pharmacy and Therapeutics (P&T) Committee Makes Changes to Preferred Drug List (PDL) Effective October 1, 2019

On June 27, 2019, the Pharmacy and Therapeutics (P&T) Committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy met to review new and existing therapeutic drug classes on the Nevada Medicaid Preferred Drug List (PDL).

The actions taken by the committee are indicated below. All changes are effective October 1, 2019. The complete PDL is posted on the "[Preferred Drug List](#)" webpage.

Drug Class	Drugs Added As Preferred	Drugs Added As Non-Preferred
Analgesics: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral	CELECOXIB CAP	NAPROXEN TAB ER SPRIX® SPR
Biologic Response Modifiers: Multiple Sclerosis Agents - Injectable		GLATIRAMER
Biologic Response Modifiers: Multiple Sclerosis Agents - Oral		MAVENCLAD® MAYZENT®
Cardiovascular Agents: Antihypertensive Agents: Vasodilators - Oral	TADALAFIL	ADCIRCA® ALYQ®
Dermatological Agents: Topical Analgesics		LICART® ZTLIDO®
Dermatological Agents: Topical Anti-Inflammatory Agents: Immunomodulators: Topical		PIMECROLIMUS
Hormones and Hormone Modifiers: Antidiabetic Agents: Insulins		INSULIN LISPRO INJ 100U/ML
Neurological Agents: Anticonvulsants		DIACOMIT®
Neurological Agents: Antiparkinsonian Agents: Dopamine Precursors (NEW)	CARBIDOPA/LEVODOPA CARBIDOPA/LEVODOPA ER CARBIDOPA/LEVODOPA ODT STALEVO®	CARBIDOPA/LEVODOPA/ENTACAPONE DUOPA™ INBRIJA™ (INH) LODOSYN® TAB RYTARY™
Ophthalmic Agents: Antiglaucoma Agents	ROCKLATAN®	
Psychotropic Agents: Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs)		PAROXETINE ER

Drug Class	Drugs Added As Preferred	Drugs Added As Non-Preferred
Respiratory Agents: Long-Acting/Maintenance Therapy	FLUTICASONE PROPIONATE/SALMETEROL POW	ADVAIR® DISKUS
Respiratory Agents: Short-Acting/Rescue Therapy		ALBUTEROL AER HFA